TP53 and neoplasm: Various genetic alterations such as the mutation activation of oncogenes (example: KRAS), the inactivation of tumor-suppressor genes (example: CDKN2A, TP53, SMAD4, BRCA2), the loss of heterozygosity during gene amplification, and telomere shortening, contributes to this [5,14].